same type of product...that is 107 is vaccine that is AUTOLOGOUS...only one host and only one recipient= COGS-cost of goods sold will be very expensive and very complicated to make which implies the same business model used ny DNDN will be used by IMUC...so sales of Provenge are not growing and they did $300M last year...GBM needs targeted approach more in line with what CLDX is doing w/ Rindopep! Do some serious DD before you lose your money in IMUC which is years away from a Marketable vaccine anyways.
CLDX is deep into P-3 w/ Rindopep and will be on the Market in 2015 likely! It is predicted that up to 40% of GBM cancers express the EGFRvIII proyein that Rindopep attacks and eliminates and thus the DOUBLE SURVIVOR times to SOC! Rindo is OFF THE SHELF which means relatively cheap to make and distribute do to its being an allogeneic vaccine!
GLTA but be careful in IMUC...its NOT BOB.....likely that will be CLDX in this space!
You have absolutely no idea what you're talking about, seriously. Your COGS argument is the exact opposite of the truth. And about DNDN, their treatment bragged of a 2(!) month advantage over SOC and went to over $50. Imuc is at least twice that and counting.
And that's only the beginning...
Woud like that as I have been long for quite some time, longer than most. But I'm not one to post on those types of websites. Nice to have those serious discussions rather than the bull that you get on these types of boards especially from day traders and shorts. Good luck with the board and I will respond to those on this site who are serious believers and long on IMUC. Good luck to the group!